Lyophilized Drugs, Reconstitution Devices and Injection Market Report 2024 - The Importance of Technology and Regulatory Factors on Commercialization and Market Access - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Lyophilized Drugs, Reconstitution Devices and Injection Markets: Products, Markets, Therapeutics, Strategies & Forecasts" report has been added to ResearchAndMarkets.com's offering.

The report is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for lyophilized injectable drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolution in Therapeutic Care

The number of drugs supplied in lyophilized form has been growing at an increased rate over the past several years, mirroring the increase in the introduction of biological drugs. Liquid drugs that require refrigeration until dispensed - a requirement referred to as the 'Cold Chain' - can be formulated as powders to avoid the cost and logistics of cold storage.

A number of factors are at play that are likely to influence the future demand picture for lyophilized drugs. Perhaps the most important is the underlying dynamics of the pharmaceutical and biotechnology marketplace as they apply to drug formulation and end user requirements.

Report Scope:

• Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
• Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
• Analyzes reconstitution technologies and market development issues
• Provides market data and forecasts to 2026
• Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
• Assesses the importance of technology and regulatory factors on commercialization and market access

Company Profiles

• Becton Dickinson
• Hospira/Pfizer
• SHL Medical
• Schott
• Vetter
• Ypsomed

Key Topics Covered:

Executive Summary

• Integrated Devices for POC Reconstitution
  • Dual Chamber Cartridges
  • Dual Chamber Injectors
  • Dual Chamber Syringes
  • Wearable Device Automated Reconstitution Systems
• Device Assessments
  • Product-Specific Devices
    • MiniQuick (Vetter)
  • Specialty Devices
    • Caverject Impulse (Hospira/Pfizer)
  • OEM Devices
    • Lyo-Ject (Vetter)
    • DCP (SHL)
    • Dual Chamber Safety Syringe (Credence Medsystems)
    • Liquid Dry (Becton Dickinson)
    • LyoTwist Trio/Vario (Ypsomed)
    • LyoTwist Trio S/Vario S (Ypsomed)
    • V-LK (Vetter)
• The Market Opportunity
  • Lyophilized Drug Market Dynamics
  • The Economics of lyophilized Drugs
  • What's Driving the Market for Lyophilized Drugs?
    • The Trend toward Self-Administration
    • Shifting Demographics
    • Innovation in Disposable Device Designs
• Competitive Landscape
• Therapeutic Demand Drivers
  • Risk Factors
• Lyophilized Drugs - Primary Packaging
  • Drug Reconstitution
    • Dual Chamber Cartridges
    • Dual Chamber Syringes
  • Prefilled Diluent Syringes
  • Multi-Step Devices
  • Human Engineering/Ergonomics
• Key Therapeutic Sector Analysis & Market Data
  • Antibiotics & Infectious Diseases
  • Immune
  • Cardiology & Blood Factors
  • Metabolic Conditions
  • Glycemic Control
  • Development Stage Dual Chamber Injectable Drug Products
  • Osteoporosis
  • Hormones
• Neurology
• Oncology
• Reproductive Health
  • Erectile Dysfunction
• Market Factors
  • Regulatory Issues
  • Healthcare Economics
• Therapeutic Segments - Data & Forecasts
  • Hormone Replacement
    • Genotropin (Pfizer)
  • Metabolic Conditions
    • Osteoporosis
  • Neurology
    • Abilify Maintena (Otsuka America Pharmaceutical)
  • Oncology
    • Lucrin (Abbott Australasia Pty)
  • Reproductive Health
    • Caverject Impulse (Hospira/Pfizer)
    • Edex/alprostadil (Actient)
    • Lupron Depot (AbbVie)
  • Other Therapeutic Segments
    • Prostap (Takeda)

For more information about this report visit https://www.researchandmarkets.com/r/9gfzp5

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.